Blood marker may predict who benefits most from gastric bypass
NCT ID NCT07241741
First seen Nov 21, 2025
Summary
This study tested whether a blood protein called PTX3 can predict how well people do after gastric bypass surgery. Researchers followed 23 adults with obesity for 6 months after surgery, measuring weight loss, insulin resistance, and inflammation. They compared results between those with high versus low PTX3 levels before surgery. The goal was to see if PTX3 could help identify who will get the most metabolic benefit from the procedure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If PTX3 levels reliably predict who will benefit most from bariatric surgery, doctors could better personalize treatment decisions for obesity.
What could go wrong
This was a very small study (23 people) with no control group, so results may not apply to everyone. The marker PTX3 is still experimental and not ready for routine use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.